Anastrozole (arimidex®), a new aromatase inhibitor for advanced breast cancer: Mechanism of action and role in management

Cancer Investigation

Volumn 16, Issue 6, 1998, Pages 385-390

  Hortobagyi, Gabriel N ^a   Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTROGEN; NITRILE; TRIAZOLE DERIVATIVE;

BIOSYNTHESIS; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGENS; FEMALE; HUMANS; NITRILES; TRIAZOLES;

EID: 0031608470     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809115778     Document Type: Article

References (27)

1. Boring CC, Squires TS, Tong T: Cancer statistics, 1992. Cancer 42:19-38, 1992.
2. National Center for Health Statistics: Vital Statistics of the United States, 1987, Vol 2, Mortality, Washington DC, U.S. Government Printing Office, 1990.
3. Ibrahim NK, Buzdar AU: Aromatase inhibitors: Current status. Am J Clin Oncol 18:407-417, 1995.
4. Glass A, Hoover RN: Changing incidence of breast cancer. J Natl Cancer Inst 80:1076-1077, 1988.
5. Santen RJ: Clinical use of aromatase inhibitors in human breast carcinoma. Steroid Biochem Mol Biol 40:247-253, 1991.
6. Harris JR, Morrow M, Bonadonna G: Cancer of the breast. In: Cancer: Principles and Practice of Oncology, 4th ed, edited by VT DeVita Jr., S Hellman, SA Rosenberg, Philadelphia, PA, JB Lippincott, 1993, pp 1264-1332.
7. McGuire WL: An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: Hormones and Cancer, Vol 15, edited by S lacobelli, New York, Raven Press, 1980, pp 337-344.
8. Bland KI, Fuchs A, Wittliss JL: Menopausal status as a factor in the distribution of estrogen and progestin receptors in breast cancer. Surg Forum 32:410-412, 1981.
9. Plourde PV, Dyroff M, Dowsett M, et al: Arimidex: A new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 53:175-179, 1995.
10. Yates RA, Dowsett M, Fisher GV, et al: Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 73:543-548, 1996.
11. Walton PL, Yates RA, Dukes M: Arimidex: an overview of a new selective nonsteroidal aromatase inhibitor. In: Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic Clinical Aspects, edited by M Motta, M Serio, pp 311-316, 1994.
12. Package Insert. Arimidex (anastrozole) tablets. 1995.
13. Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in post-menopausal women with advanced breast cancer: Results of an overview analysis of two phase III trials. J Clin Oncol 14:2000-2011, 1996.
14. Jonat W, Howell A, Blomqvist C, et al: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404-412, 1996.
15. Plourde PV, Dyroff M, Dukes M: Arimidex: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30:103-111, 1994.
16. Goss PE, Gwyn KMEH: Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 12:2460-2470, 1994.
17. Brodie AMH: Aromatase, its inhibitors and their use in breast cancer treatment. Pharmacol Ther 60:501-515, 1993.
18. Santen RJ, Leszcynski D, Tilson-Mallet N, et al: Enzymatic control of estrogen production in human breast cancer: Relative significance of aromatase versus sulfatase pathways. Ann NY Acad Sei 464:126-137, 1986.
19. O'Neill JS, Miller WR: Aromatase activity in breast adipose tissue from women with benign and malignant disease. Br J Cancer 56:601-604, 1987.
20. Bradlow HL: A reassessment of the role of breast tumor aromatization. Cancer Res 42:3382s-3386s, 1982.
21. Geisler J, Lonning P, Dowsett M, et al: A randomized, doubleblind, multicentre, cross-over trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 5 mg p.o. o.d.) in postmenopausal women with breast cancer. Nottingham Breast Cancer Meeting-Zeneca Symposium, Nottingham, UK, 1995.
22. Robertson J, Williams M, Todd J: Factors predicting the response of patients with advanced breast cancer endocrine. Eur J Cancer Clin Oncol 23:469175, 1989.
23. Muss HB, Case LD, Capizzi RL, et al: High- versus standarddose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association. J Clin Oncol 8:1797-1805, 1990.
24. Mercer PM, Ebbs SR, Fraser SC, et al: Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. Eur J Surg Oncol 19:254-258, 1983.
25. Pronzato P, Rubagotti A, Amoroso D, et al: Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation. Am J Clin Oncol 16:522-525, 1993.
26. Congdon J, Green S, O'Sullivan J, et al: Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer. Proc Am Soc Clin Oncol 10:43, 1991.
27. Manni A: Pharmacologie manipulation of steroid hormones. Endocrinol Metab Clin North Am 20:825-844, 1991.